Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsSecurities - TradableShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Common Equity: 2022-2025

Historic Common Equity for Praxis Precision Medicines (PRAX) over the last 4 years, with Sep 2025 value amounting to $343.5 million.

  • Praxis Precision Medicines' Common Equity fell 10.23% to $343.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $343.5 million, marking a year-over-year decrease of 10.23%. This contributed to the annual value of $445.4 million for FY2024, which is 539.38% up from last year.
  • As of Q3 2025, Praxis Precision Medicines' Common Equity stood at $343.5 million, which was down 15.02% from $404.2 million recorded in Q2 2025.
  • In the past 5 years, Praxis Precision Medicines' Common Equity registered a high of $445.4 million during Q4 2024, and its lowest value of $64.5 million during Q1 2023.
  • Over the past 3 years, Praxis Precision Medicines' median Common Equity value was $343.5 million (recorded in 2025), while the average stood at $271.9 million.
  • In the last 5 years, Praxis Precision Medicines' Common Equity crashed by 66.25% in 2023 and then skyrocketed by 539.38% in 2024.
  • Over the past 4 years, Praxis Precision Medicines' Common Equity (Quarterly) stood at $76.1 million in 2022, then fell by 8.46% to $69.7 million in 2023, then spiked by 539.38% to $445.4 million in 2024, then fell by 10.23% to $343.5 million in 2025.
  • Its Common Equity was $343.5 million in Q3 2025, compared to $404.2 million in Q2 2025 and $439.2 million in Q1 2025.